Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective (Q38248427)

1 September 2017

1 reference

title

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective (English)

1 reference

1 September 2017

main subject

acute myeloid leukemia

1 reference

Masamitsu Yanada

1

1 reference

1 September 2017

publication date

12 September 2014

1 reference

International Journal of Hematology

1 September 2017

published in

1 reference

1 September 2017

volume

101

1 reference

1 September 2017

issue

3

1 reference

1 September 2017

page(s)

243-254

1 reference

Acute myeloid leukemia in older adults

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

A novel hierarchical prognostic model of AML solely based on molecular mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

The myth of the second remission of acute leukemia in the adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Pa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Grup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Cord-blood engraftment with ex vivo mesenchymal-cell coculture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Marrow transplantation from related donors other than HLA-identical siblings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-014-1657-0

Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (S

21 January 2018

1 reference

12 December 2020

Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marro

1 reference

12 December 2020

Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion

1 reference

12 December 2020

MISMATCHED FAMILY DONORS FOR BONE-MARROW TRANSPLANTATION AS TREATMENT FOR ACUTE LEUKAEMIA

1 reference

12 December 2020

1 reference

12 December 2020

T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantati

1 reference

12 December 2020

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia

1 reference

12 December 2020

Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy

1 reference

12 December 2020

Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osse

1 reference

12 December 2020

Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy

1 reference

12 December 2020

A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group

1 reference

12 December 2020

Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A

1 reference

12 December 2020

Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission

1 reference

12 December 2020

Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.

1 reference

12 December 2020

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories

1 reference

12 December 2020

Impact of a single human leucocyte antigen (HLA) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the HLA Working Group of the Japan Society for Blood and M

1 reference

12 December 2020

Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission

1 reference

12 December 2020

Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study

1 reference

12 December 2020

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission

1 reference

12 December 2020

1 reference

12 December 2020

Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings

1 reference

12 December 2020

The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies

1 reference

12 December 2020

Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics

1 reference

12 December 2020

Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies

1 reference

12 December 2020

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission

1 reference

12 December 2020

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype

1 reference

12 December 2020

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience

1 reference

12 December 2020

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases

1 reference

12 December 2020

Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia

1 reference

12 December 2020

No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

12 December 2020

10.1007/S12185-014-1657-0

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1031936200

0 references

1 reference